Advertisement

 

 

ASTRO: No Survival Benefit for Adding EBT to Brachytherapy

ASTRO: No Survival Benefit for Adding EBT to Brachytherapy
Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

WEDNESDAY, Sept. 28, 2016 (HealthDay News) — Among men with intermediate-risk prostate cancer, the addition of external beam therapy (EBT) to transperineal interstitial permanent brachytherapy (B) does not improve five-year progression-free survival, according to a study presented at the annual meeting of the American Society for Radiation Oncology, held from Sept. 25 to 28 in Boston.

Bradley R. Prestidge, M.D., from the DePaul Medical Center in Norfolk, Va., and colleagues randomized men with prostate cancer to receive 45 Gy partial pelvis EBT + B or B alone. Five hundred eighty-eight men were randomized (287 EBT + B eligible and 292 B eligible); patients were followed for a median of 6.7 years.

The researchers found that five-year progression-free survival was 85 percent for the EBT + B arm and 86 percent for the B arm at the fifth interim analysis of 443 patients with five years of follow-up (hazard ratio, 1.02; futility P = 0.0006). The Data Monitoring Committee recommended early release for the initial reporting of the primary end point. Similar acute overall ≥ grade 3 toxicity was seen (8 percent for EBT + B and B). Overall ≥ grade 3 late toxicity was 12 and 7 percent for EBT + B and B, respectively.

“These findings suggest that many men with intermediate risk prostate cancer can be well managed with seed implant alone and do not require the addition of external beam radiation,” Prestidge said in a statement.

Press Release
More Information

Copyright © 2016 HealthDay. All rights reserved.
healthday

Submit a Comment

Your email address will not be published. Required fields are marked *

five × 2 =

[ HIDE/SHOW ]